News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Leukemia & Lymphoma Society To Honor BioVision, Inc.'s Dr. Christopher B. Wood


10/19/2005 5:09:54 PM

NEW YORK--(BUSINESS WIRE)--May 18, 2005--The Leukemia & Lymphoma Society's New York City Chapter will host the Society's Annual Bill Bernbach Memorial Dinner, in part, to honor Dr. Christopher B. Wood, Chairman and CEO of Bioenvision, Inc. (Nasdaq:BIVN) on May 18, 2005. The Society is honoring Dr. Wood for his work in developing clofarabine, which recently received FDA approval for the first new children's leukemia drug developed in a decade for the treatment of children with leukemia. "The road to approval has been challenging and we are delighted to celebrate by honoring the man who had the foresight and the vision to put clofarabine into clinical development" stated David Luci, CFO and General Counsel of Bioenvision. He added, "we are pleased to continue to raise awareness in our local community."

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES